Is Telix Pharmaceuticals (ASX:TLX) Trading Near its 52-Week High or Low?

Sonal Goyal

09 July 2026 11:47 PM AEST

Is Telix Pharmaceuticals (ASX:TLX) Trading Near its 52-Week High or Low?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) shares gained 2.17% during the latest trading session.
The biotechnology stock reached its intraday high before the latest quoted price.
Telix Pharmaceuticals' market capitalisation stood at approximately AUD 5.62 billion.

Telix Pharmaceuticals Limited (ASX:TLX) shares traded higher during the latest trading session, rising 2.17% to AUD 16.940 from the previous close of AUD 16.580. The biotechnology company's shares recorded positive price movement as investors monitored activity across the Pharmaceuticals, Biotechnology & Life Sciences sector.

Listed on the Australian Securities Exchange (ASX), Telix Pharmaceuticals had a market capitalisation of approximately AUD 5.62 billion based on the latest available trading data.

TLX Shares Advance During Trading

Telix Pharmaceuticals shares traded between an intraday low of AUD 16.390 and a high of AUD 16.940 during the session. The latest quoted price matched the day's high, while the stock was bid at AUD 16.880 and offered at AUD 16.940.

The gain of AUD 0.360 represented a 2.17% increase from the previous closing price. Despite the latest advance, the stock remained below its 52-week high of AUD 25.870 while trading above its 52-week low of AUD 8.260.

Trading Volume Below Average

The stock recorded trading volume of 982,794 shares during the latest session. This was below the average daily trading volume of approximately 2.54 million shares, indicating lighter trading activity than the stock's typical daily turnover.

Telix Pharmaceuticals has 339.38 million ordinary fully paid shares on issue, resulting in a market capitalisation of approximately AUD 5.62 billion at the latest trading price.

Trading volume, together with price movements, is commonly monitored by market participants to assess investor activity during a trading session.

Company Overview

Telix Pharmaceuticals Limited operates in the Pharmaceuticals, Biotechnology & Life Sciences industry group and has been listed on the ASX since 15 November 2017 under the ticker TLX.

The company trades as ordinary fully paid shares and carries the International Securities Identification Number (ISIN) AU000000TLX2.

Companies in the biotechnology sector may experience share price movements influenced by clinical trial outcomes, regulatory decisions, product approvals, research developments, earnings announcements, and broader market sentiment.

Market Snapshot

Telix Pharmaceuticals recorded gains during the latest trading session, with the stock finishing at its intraday high of AUD 16.940. Although the shares advanced on the day, they continue to trade within a broad 52-week range of AUD 8.260 to AUD 25.870.

Trading activity remained below the stock's average daily volume, while investors continued monitoring developments across the healthcare and biotechnology sectors.

Key Risks

Clinical trial outcomes may influence investor sentiment.
Regulatory approvals can affect commercial timelines.
Product development delays may impact future growth.
Market volatility can affect short-term share price performance.

Summary

Telix Pharmaceuticals (ASX: TLX) shares gained 2.17% to AUD 16.940 during the latest trading session after closing at AUD 16.580 previously. The stock traded between AUD 16.390 and AUD 16.940, with trading volume of 982,794 shares, below its average daily turnover. The company currently has a market capitalisation of approximately AUD 5.62 billion.

FAQs

Q: What was Telix Pharmaceuticals' latest share price?

A:Telix Pharmaceuticals shares traded at AUD 16.940, up 2.17% from the previous closing price of AUD 16.580.

Q: What is Telix Pharmaceuticals' market capitalisation?

A:Telix Pharmaceuticals had a market capitalisation of approximately AUD 5.62 billion during the latest trading session.

Q: What is Telix Pharmaceuticals' 52-week trading range?

A:Telix Pharmaceuticals shares have traded between AUD 8.260 and AUD 25.870 over the past 52 weeks.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.